-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 19, 2021, Gilead Sciences announced that it has submitted a biologics license application (BLA) for bulevirtide to the US FDA
Hepatitis D is the most serious type of viral hepatitis.
The BLA submission is based on positive data obtained from a Phase 2 clinical trial and an ongoing Phase 3 clinical trial
The interim results of the trial showed that after 24 weeks of treatment, the proportion of patients in the 2 mg bulevirtide group achieving a combined virological and biochemical response was 36.
The safety profile of the drug is consistent with previous studies, and no serious adverse events (AE) have been reported
"Our goal is to provide safe and effective treatments for people with the most severe forms of chronic viral hepatitis, which can quickly progress to serious complications, including fibrosis, cirrhosis, and liver cancer, and increase the risk of death
Reference materials:
[1] Gilead Submits Biologics License Application to US Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta.
